Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM ESTCompany ParticipantsJeffrey Poulton - CFO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results